163 related articles for article (PubMed ID: 34622951)
1. Circulating DNA changes are predictive of disease progression after transarterial chemoembolization.
Sefrioui D; Verdier V; Savoye-Collet C; Beaussire L; Ghomadi S; Gangloff A; Goria O; Riachi G; Montialoux H; Schwarz L; Tuech JJ; Frebourg T; Michel P; Sarafan-Vasseur N; Di Fiore F
Int J Cancer; 2022 Feb; 150(3):532-541. PubMed ID: 34622951
[TBL] [Abstract][Full Text] [Related]
2. Usefulness of Cell-Free Human Telomerase Reverse Transcriptase Mutant DNA Quantification in Blood for Predicting Hepatocellular Carcinoma Treatment Efficacy.
Muraoka M; Maekawa S; Katoh R; Komiyama Y; Nakakuki N; Takada H; Matsuda S; Suzuki Y; Sato M; Tatsumi A; Miura M; Amemiya F; Shindo H; Takano S; Fukasawa M; Yamauchi K; Yamaguchi T; Nakayama Y; Inoue T; Enomoto N
Hepatol Commun; 2021 Nov; 5(11):1927-1938. PubMed ID: 34558819
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of Tumor Response Using Alpha-fetoprotein and Des-gamma-carboxy Prothrombin in Hepatocellular Carcinoma Patients Who Underwent Transarterial Chemoembolization.
Cerban R; Ester C; Iacob S; Paslaru L; Dumitru R; Grasu M; Constantin G; Popescu I; Gheorghe L
Chirurgia (Bucur); 2018; 113(4):524-533. PubMed ID: 30183583
[TBL] [Abstract][Full Text] [Related]
4. Postintervention Interleukin-6 (IL-6) Level, Rather than the Pretreatment or Dynamic Changes of IL-6, as an Early Practical Marker of Tumor Response in Hepatocellular Carcinoma Treated with Transarterial Chemoembolization.
Wu Y; Fan W; Xue M; Zhong B; Zhang S; Wang Y; Yao W; Zhao Y; Li J
Oncologist; 2019 Dec; 24(12):e1489-e1495. PubMed ID: 31249138
[TBL] [Abstract][Full Text] [Related]
5. Transarterial chemoembolization in unresectable hepatocellular carcinoma--assessing the factors affecting the survival: An audit from a tertiary care center in northern India.
Agarwal A; Yadav AK; Kumar A; Gupta S; Panwala HK; Redhu N; Hariprasad S; Ranjan P; Arora A; Gupta A
Indian J Gastroenterol; 2015 Mar; 34(2):117-26. PubMed ID: 25937484
[TBL] [Abstract][Full Text] [Related]
6. Early Prediction of the Outcome Using Tumor Markers and mRECIST in Unresectable Hepatocellular Carcinoma Patients Who Underwent Transarterial Chemoembolization.
Ichikawa T; Machida N; Sasaki H; Tenmoku A; Kaneko H; Negishi R; Oi I; Fujino MA
Oncology; 2016; 91(6):317-330. PubMed ID: 27784014
[TBL] [Abstract][Full Text] [Related]
7. Tumor Markers AFP, AFP-L3, and DCP in Hepatocellular Carcinoma Refractory to Transcatheter Arterial Chemoembolization.
Hiraoka A; Ishimaru Y; Kawasaki H; Aibiki T; Okudaira T; Toshimori A; Kawamura T; Yamago H; Nakahara H; Suga Y; Azemoto N; Miyata H; Miyamoto Y; Ninomiya T; Hirooka M; Abe M; Matsuura B; Hiasa Y; Michitaka K
Oncology; 2015; 89(3):167-74. PubMed ID: 25999038
[TBL] [Abstract][Full Text] [Related]
8. Prognostic Value of Alpha-Fetoprotein in Patients Who Achieve a Complete Response to Transarterial Chemoembolization for Hepatocellular Carcinoma.
Lee JS; Chon YE; Kim BK; Park JY; Kim DY; Ahn SH; Han KH; Kang W; Choi MS; Gwak GY; Paik YH; Lee JH; Koh KC; Paik SW; Kim HY; Kim TH; Yoo K; Ha Y; Kim MN; Lee JH; Hwang SG; Kim SS; Cho HJ; Cheong JY; Cho SW; Park SH; Heo NY; Hong YM; Yoon KT; Cho M; Park JG; Kang MK; Park SY; Kweon YO; Tak WY; Jang SY; Sinn DH; Kim SU;
Yonsei Med J; 2021 Jan; 62(1):12-20. PubMed ID: 33381930
[TBL] [Abstract][Full Text] [Related]
9. Hepatic resection after transarterial chemoembolization increases overall survival in large/multifocal hepatocellular carcinoma: a retrospective cohort study.
Chen J; Lai L; Lin Q; Huang W; Cai M; Zhu K; Huang M
Oncotarget; 2017 Jan; 8(1):408-417. PubMed ID: 27880724
[TBL] [Abstract][Full Text] [Related]
10. 25-OH-vitamin D deficiency identifies poor tumor response in hepatocellular carcinoma treated with transarterial chemoembolization.
Wu YQ; Fan WZ; Xue M; Guo J; Wei JL; Wang Y; Yao W; Zhao Y; Li JP
Clin Transl Oncol; 2020 Jan; 22(1):70-80. PubMed ID: 31183764
[TBL] [Abstract][Full Text] [Related]
11. Prognostic significance of alpha-fetoprotein status in the outcome of hepatocellular carcinoma after treatment of transarterial chemoembolization.
Wang Y; Chen Y; Ge N; Zhang L; Xie X; Zhang J; Chen R; Wang Y; Zhang B; Xia J; Gan Y; Ren Z; Ye S
Ann Surg Oncol; 2012 Oct; 19(11):3540-6. PubMed ID: 22532305
[TBL] [Abstract][Full Text] [Related]
12. Validation and evaluation of clinical prediction systems for first and repeated transarterial chemoembolization in unresectable hepatocellular carcinoma: A Chinese multicenter retrospective study.
Wang ZX; Wang EX; Bai W; Xia DD; Mu W; Li J; Yang QY; Huang M; Xu GH; Sun JH; Li HL; Zhao H; Wu JB; Yang SF; Li JP; Li ZX; Zhang CQ; Zhu XL; Zheng YB; Wang QH; Li J; Yuan J; Li XM; Niu J; Yin ZX; Xia JL; Fan DM; Han GH; On Behalf Of China Hcc-Tace Study Group
World J Gastroenterol; 2020 Feb; 26(6):657-669. PubMed ID: 32103874
[TBL] [Abstract][Full Text] [Related]
13. Noninvasive detection of tumor-associated mutations from circulating cell-free DNA in hepatocellular carcinoma patients by targeted deep sequencing.
Liao W; Yang H; Xu H; Wang Y; Ge P; Ren J; Xu W; Lu X; Sang X; Zhong S; Zhang H; Mao Y
Oncotarget; 2016 Jun; 7(26):40481-40490. PubMed ID: 27248174
[TBL] [Abstract][Full Text] [Related]
14. Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study.
Xing M; Webber G; Prajapati HJ; Chen Z; El-Rayes B; Spivey JR; Pillai AA; Kim HS
J Gastroenterol Hepatol; 2015 Jul; 30(7):1167-74. PubMed ID: 25675849
[TBL] [Abstract][Full Text] [Related]
15. Rate and Predictive Factors for Sustained Complete Response after Selective Transarterial Chemoembolization (TACE) in Patients with Hepatocellular Carcinoma.
Bannangkoon K; Hongsakul K; Tubtawee T; McNeil E; Sriplung H; Chongsuvivatwong V
Asian Pac J Cancer Prev; 2018 Dec; 19(12):3545-3550. PubMed ID: 30583681
[TBL] [Abstract][Full Text] [Related]
16. Circulating Cell-Free DNA and DNA Integrity as Molecular Diagnostic Tools in Hepatocellular Carcinoma.
Elzehery R; Effat N; El Farahaty R; Elsayed Farag R; Abo-Hashem EM; Elhelaly R
Am J Clin Pathol; 2022 Aug; 158(2):254-262. PubMed ID: 35403666
[TBL] [Abstract][Full Text] [Related]
17. Alpha-fetoprotein assessment for hepatocellular carcinoma after transarterial chemoembolization.
Tian M; Zhang X; Huang G; Fan W; Li J; Zhang Y
Abdom Radiol (NY); 2019 Oct; 44(10):3304-3311. PubMed ID: 31250181
[TBL] [Abstract][Full Text] [Related]
18. Copy number profiling of circulating free DNA predicts transarterial chemoembolization response in advanced hepatocellular carcinoma.
Dong X; Chen G; Huang X; Li Z; Peng F; Chen H; Zhou Y; He L; Qiu L; Cai Z; Liu J; Liu X
Mol Oncol; 2022 May; 16(10):1986-1999. PubMed ID: 34939323
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolization.
Lee YK; Kim SU; Kim DY; Ahn SH; Lee KH; Lee DY; Han KH; Chon CY; Park JY
BMC Cancer; 2013 Jan; 13():5. PubMed ID: 23282286
[TBL] [Abstract][Full Text] [Related]
20. Comparison of transarterial chemoembolization in patients with unresectable, diffuse vs focal hepatocellular carcinoma.
Lopez RR; Pan SH; Hoffman AL; Ramirez C; Rojter SE; Ramos H; McMonigle M; Lois J
Arch Surg; 2002 Jun; 137(6):653-7; discussion 657-8. PubMed ID: 12049535
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
